Eikon Therapeutics
Edit

Eikon Therapeutics

https://eikontx.com/
Last activity: 02.06.2023
Categories: DrugDataChemicalApp3DTimeTechnologyPlatformLivingEngineering
Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells. By directly measuring the effects of chemical compounds on the behavior of protein molecules in a live cellular environment, Eikon’s landmark assays facilitate the highly sensitive identification of compound-protein interactions that could not be identified through traditional assays, thereby unlocking otherwise intractable classes of proteins as drug targets. Furthermore, the ability to directly visualize protein mechanisms in disease coupled with the extraordinarily high-powered high-content data sets generated by Eikon’s drug-screening technology enable an unprecedented opportunity to quantitatively explore novel biology in the living cell. These insights facilitate creation and application of data-driven hypotheses to the discovery of life-saving therapies. Eikon is seeking adventurous, passionate and creative team members eager to apply their talents to empower interdisciplinary scientific exploration, inaugurate a radical drug-discovery paradigm, and ultimately create novel medicines. To learn more about open positions, please visit: https://eikontx.com/team#positions
Followers
686
Followers
6.43K
Mentions
13
Location: United States, California, Hayward
Employees: 11-50
Total raised: $666M
Founded date: 2019

Investors 6

Funding Rounds 2

DateSeriesAmountInvestors
07.01.2022Series B$518M-
06.05.2021Series A$148M-

Mentions in press and media 13

DateTitleDescriptionSource
02.06.2023Eikon Therapeutics Acquires Global Rights to Clinical-Stage ...New assets establish foundation for Eikon’s expanding pipeline of in-house and acquired drug candida...aithority....
01.06.2023Impact Therapeutics Entered into Global Partnership with Eik...SHANGHAI and HAYWARD, Calif., June 1, 2023 /PRNewswire/ -- IMPACT Therapeutics ("Impact"),...en.prnasia...
07.01.2022US-based biopharmaceutical startup Eikon Therapeutics raises...Eikon Therapeutics, Inc., a biopharmaceutical startup employing revolutionary technology at the inte...vcbay.news...
06.01.2022Early stage startups doubled their funding in 2021This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ...fortune.co...
06.01.2022Eikon Therapeutics Announces $517.8 Million Series B Raise-tcgcrossov...
06.01.2022‘How can you understand life if you don’t look at it live?’ ...Adam Goulburn, a partner at Lux Capital, was first struck by Eikon Therapeutics’ pitch to use super ...techcrunch...
06.01.2022Early stage startups doubled their funding in 2021This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ...fortune.co...
06.01.2022Eikon Therapeutics, Inc. announced that it has received $517...On January 6, 2022, Eikon Therapeutics, Inc. closed the transaction. The company has received $517,7...marketscre...
06.01.2022Eikon Therapeutics Announces $517.8 Million Series B Raise a...Eikon Therapeutics, Inc., a pioneer in the application of live-cell super-resolution microscopy to d...marketscre...
06.05.2021Eikon Therapeutics lands $148M Series AThe Column Group has led a $148 million round for Eikon Therapeutics, the developer of a drug discov...pitchbook....
Show more

Reviews 0

Sign up to leave a review

Sign up Log In